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Abstract
Background: The clinical prospects of  hydroxyurea therapy in the management of  sickle cell disease (SCD) require evaluation 
in the Nigerian setting to develop indigenous guidelines. This survey examines the pattern of  hydroxyurea therapy, its clini-
co-haematologic benefits and safety profile in Nigerian SCD subjects.
Methods: A cross sectional pilot survey was carried out among 60 adult SCD subjects over 3 months. Data on clinical pheno-
types, relevant haematological parameters and details of  hydroxyurea therapy were obtained using a structured questionnaire 
through an interview process and case file review.
Results: The median age was 30 years. Thirty-four (56.7%) of  the subjects are aware of  hydroxyurea therapy in SCD. Twen-
ty-four (40%) SCD patients had previously used hydroxyurea. Only 4 subjects were fully compliant. Reasons for non-compliance 
included poor knowledge and lack of  funds. In particular, hydroxyurea reduced leucocyte count and increased mean red cell 
volume (MCV) in compliant subjects.   
Conclusion: Hydroxyurea use is low among Nigerian SCD subjects despite its proven efficacy/clinical prospects in the devel-
oped nations. Large scale multicenter studies and clinical trials are needed to form a basis for developing standard local treatment 
protocol for its use.
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Introduction
Sickle cell disease (SCD) remains a major public health 
challenge, affecting over 3 million Nigerians1,2. Estimates 
put SCD prevalence between 2 and 3%, in a population 
of  170 million Nigerians2-4. Low levels of  awareness/
knowledge, poor case finding strategies and sub-optimal 
treatment continue to fuel morbidity and mortality rates 
in the country5-9. The introduction of  novel agents such 
as hydroxyurea has greatly impacted on disease outcome 
in developed climes such as US10-13. There are indications 
that hydroxyurea is under utilized in the Nigerian set-
ting14,15.
Recent studies suggest that Nigerian SCD is still associ-
ated with significant pain burden and other morbidities, 
which might be reduced through appropriate interven-
tions such as hydroxyurea9,14,16-18. Giving the constant risk 
of  exposure to precipitants such as malaria and other 
infections, there is a palpable need to critically evaluate, 
standardize, advocate and monitor interventional thera-
pies such as chronic transfusions, hydroxyurea and hae-
mopoietic stem cell transplant in the Nigerian setting. 
Data on the level of  hydroxyurea awareness, pattern of  
use and benefits is needed.
Since its approval by FDA in 1998 for treatment of  mod-
erate to severe sickle cell disease, hydroxyurea (otherwise 
called hydroxycarbamide) has shown immense benefits 
in ameliorating SCD19-21. Hydroxyurea modifies the com-
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plex pathophysiology of  SCD through multiple mecha-
nisms including induction of  fetal haemoglobin produc-
tion, improving cellular hydration, marrow suppression 
(reduction of  leucocyte and platelet counts), anti-adhe-
sive properties and production of  nitric oxide (vasodi-
lator)19,22. Clinically, this translates to reduced frequency 
and intensity of  bone pain crisis, hospitalizations, blood 
transfusions, thus better quality of  life20,23,24.
This study evaluates the level of  awareness, drug use pat-
tern, clinic-laboratory benefits, level of  compliance and 
safety/toxicity profile of  hydroxyurea in a cross section 
of  Nigerian SCD patients.
 
Methodology
This is a hospital-based, pilot survey among 60 SCD sub-
jects seen at the University of  Benin Teaching Hospital, 
Benin City, Nigeria. Adult SCD subjects in steady (qui-
escent) state were recruited into the study in a consecu-
tive manner after a detailed explanation of  the intended 
study and consent obtained. The study was conducted 
according to the standard of  the institution’s ethics re-
view board. The study was conducted over a period of  
three months between May and July 2015 at the adult 
Haematology out-patient department of  the hospital. All 
subjects were diagnosed on the basis of  their clinical phe-
notypes, alkaline haemoglobin electrophoresis and other 
ancillary tests.
Data was collected from each participant using a struc-
tured interviewer-administered questionnaire through an 
interview process coupled with case file review. Subjects 
with history of  SCD crisis or any other acute illness in 
the preceding 4-6 weeks were excluded. Data collected 
included details on bio-data, clinical history of  SCD in 
the preceding one year including previous blood trans-
fusions, awareness about hydroxyurea, haematological 
parameters, history of  hydroxyurea use (dose and dura-
tion of  use), associated adverse reactions, and possible 
reasons for non-compliance. Haematological parameters 
were either carried out on the day of  the interview or 
within the preceding one month of  the sampling. Param-
eters included total leucocyte count (TLC), absolute neu-
trophil count (ANC), platelet count (PLT), haemoglobin 
concentration (HB), haematocrit (HCT), Mean corpuscu-
lar volume (MCV), red cell distribution width (RDW) and 
fetal haemoglobin levels (%HbF), where available.
Descriptive and inferential statistics were performed us-
ing Statistical Package for Social Sciences (SPSS, version 
16), Chicago, USA. Differences in the mean of  outcome 
variables such as annual rates of  bone pain crisis (BPC), 
hospitalizations and haemogram among subjects with his-
tory of  regular versus irregular/non use of  hydroxyurea 
were compared using Mann Whitney U test. Hypothesis 
testings were performed at a probability level of  5% (p 
value = 0.05). Results are presented in frequencies and 
tables.
Results
The median age of  the study participants is 30 years, 
with a male:female ratio of  1:1.86. Most (86.7%) had 
haemoglobin SS disease. The annual rates of  bone pain 
crisis, hospitalizations and blood transfusions among the 
study participants were 3.73, 1.53 and 2.15 respectively. 
The mean TLC, ANC, PLT, HB, HCT, MCV and RDW 
among the study participants were 9713/ul, 5366/ul, 
286000/ul, 8.26g/dl, 25.42%, 78.93fl, 20.89% respective-
ly. Only two of  the subjects had done a fetal haemoglobin 
assay prior to the study, giving a mean fetal haemoglobin 
level of  17.6%.
About 57% had heard about hydroxyurea, while 40% (24 
subjects) had a used it (Table 1). Only 20 subjects (33.3%) 
were currently using hydroxyurea according to physician 
recommendations. Only 4 of  these 20 subjects used the 
drug regularly as prescribed by the doctor. The median 
duration on therapy was 12 months. Reasons for non 
compliance with therapy included poor/misinformation, 
lack of  funds to procure drugs, irregular follow-ups, fear 
of  unknown side effects, being tired of  drugs and faith 
healing (Table 1). Four of  24 subjects that used hydroxy-
urea experienced side effects such as skin rashes, skin hy-
perpigmentation, blurred vision and dizziness (Table 1).
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Table 1: details regarding hydroxyurea therapy 
 
Variables   Frequency(n) Percentage(%) 
History of use       
  Never Used 36 60.0 
  Past Use 4 6.7 
  Current Use 20 33.3 
        
Duration of use (months)     
  Less than 6 months 8 33.3 
  6 months or more 16 66.7 
Mean(SEM)=25.71(6.44) , Median=12 , Min=1 , Max=120 
        
Level of compliance*     
  Regular 4 20.0 
  Not Regular 16 80.0 
        
Reasons for non-compliance**     
  Poor/misinformation 3 12.5 
  Lack of funds 4 16.7 
  Adverse reactions 1 4.2 
  Poor clinic attendance 3 12.5 
  No reason, feels okay 3 12.5 
  Fear of unknown 
effects like cancer 
3 12.5 
  Dislike for drugs-
Tired of drugs 
3 12.5 
  Faith healing 2 8.3 
        
Adverse reactions**     
  Skin 
hyperpigmentation 
1 4.2 




  Skin Rashes 1 4.2 
  None 20 83.3 
 
N = 60 (100%), *only 20 subject on current use of hydroxyurea, **multiple responses, 24 subjects with history of Hydroxyurea use 
The mean dose at commencement of  hydroxyurea thera-
py was 10.61mg/kg. The mean dose as at the time of  the 
study was 13.49mg/kg (Table 2). The most frequent in-
dication for commencement of  hydroxyurea therapy was 
frequent/severe vaso-occlusive crisis (Table 2). Four of  
the subjects discontinued hydroxyurea based on doctors’ 
recommendation. Termination of  therapy was mostly re-
lated to conception/fertility issues (Table 2).
The mean annual rate of  BPC among regular hydroxy-
urea users and irregular/non-users was 2.25 and 3.84 (p 
value > 0.05), while the mean annual transfusion rates 
were 1 and 1.57 respectively (p value > 0.05). The mean 
TLC of  regular hydroxyurea users and irregular/non-us-
ers was 6050 and 9884/ul respectively. While the mean 
MCV of  regular and irregular/non-users was 103.6 and 
77.8 fl respectively. The mean difference of  TLC was sig-
nificantly lower in subjects who used hydroxyurea reg-
ularly (p values of  0.024). Mean MCV was significantly 
higher in regular users, with a p value of  0.018.
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Table 2: Physcian’s pattern of hydroxyurea prescription 
 
Variables   Frequency(n) Percentage (%) 
Starting dose (mg/kg/day)     
  Less than 10mg/kg 15 62.5 
  10 – 20 mg/kg 9 37.5 
  >20mg/kg - - 
Mean(SD)=10.61(3.31), Median=9.01, Min=7.35, Max=17.24 
  
Current dose (mg/kg/day)*     
  Less than 10mg/kg 5 25.0 
  10 – 20 mg/kg 15 75.0 
  >20mg/kg - - 
Mean(SD)= 13.49(3.73), Median=15.05, Min=7.81, Max=17.86 
  
Indications for commencement of 
hydroxyurea** 
    
  Frequent/Severe VOC 19 79.2 
  Moderate Disease 3 12.5 
  High leucocyte/platelet 
Counts 
1 4.2 
  Severe symptomatic 
anaemia 
1 4.2 
  Severe/Recurrent ACS 1 4.2 
        
Indications for discontinuation of hydroxyurea     
  Conception/Fertility 3 12.5 
  Unbearable Reactions 1 4.2 
        
        
 
N=24(40% of all subjects), *20 subjects on current use, **multiple responses 
  
Discussion
The age, sex and haemoglobin phenotype distribution of  
subjects in this study is comparable to findings from ear-
lier local studies16,25. The mean rate of  bone pain crisis 
and hospitalisation in index study were 3.73 and 1.53 per 
annum respectively. As suggested by prior local studies, 
Nigerian SCD is still associated with significant pain bur-
den among affected subjects16. Approximately 72% expe-
rienced at least one episode of  BPC in the preceding year. 
Again, this observation is in tandem with an earlier survey 
on BPC rate in which 67% of  SCD patients experienced 
one or more episodes in the preceding year16. Platt et al 
reported a slightly lower percentage of  about 60% as at 
1991 in the US26. In a US clinical trial published in 1995, 
hydroxyurea caused a 44% reduction in median annual 
rate of  painful crisis, with a corresponding decrease in 
frequency of  acute hospitalisations for painful crisis27. 
Hydroxyurea reduced the mean annual rate of  BPC by 
41% in index study. Hydroxyurea has been shown to 
shorten duration of  hospitalizations resulting from acute 
pain crisis and the subsequent net requirement for opioid 
analgesia35.
There is a moderate level (about 57%) of  awareness re-
garding hydroxyurea among the subjects. Forty percent 
(24 subjects) had been started on hydroxyurea by phy-
sicians, although therapy was discontinued in 4 of  the 
subjects mostly due to fertility related/conception issues. 
There is a high level of  non-compliance among the sub-
jects as only 4 (20%) were regular on therapy. Reasons 
for non compliance were majorly related to poor health 
seeking behaviours among the subjects including poor in-
formation/misinformation regarding drug use, irregular 
clinic follow-ups, dislike for drugs. However, economic 
reason (poor finance) was the more frequent reason for 
non-compliance with therapy. There is need to evaluate 
in greater details health seeking practices among Nigerian 
SCD subjects, with a view to proffering effective solu-
tions for improved care of  affected persons.
This survey observed a lower rate of  BPC and hospital-
ization in subjects that used hydroxyurea regularly, though 
were not statistically significant. However, no particular 
inferences can be drawn due to the relatively small num-
ber of  regular users. A well-designed, longitudinal study 
will be required to evaluate the clinical and laboratory ef-
fects of  hydroxyurea among indigenous Africans better. 
As well, the influence of  potential confounders such as 
hemoglobin phenotypes, baseline fetal haemoglobin lev-
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els, age, gender, steady state blood cell counts in this sur-
vey participants cannot be down played, thus reducing 
plausible inferential conclusions from this survey.
Similarly, this survey observed significantly lower lev-
els of  TLC in subjects who took hydroxyurea regularly. 
This is a desirable effect since heightened leucocyte and 
platelet counts has been shown to contribute to chron-
ic morbidities and worse clinical outcomes, even in local 
settings28-31. In this vain, high steady state leucocyte and 
platelet counts have been suggested as indications for 
commencement of  hydroxyurea14,19,32. The mean corpus-
cular volume of  red cells was significantly higher in sub-
jects using hydroxyurea regularly. Again, this is expected 
as increase in red cell fetal haemoglobin level corresponds 
to increased MCV. Thus, oval macrocytosis may be an 
indirect evidence of  compliance with therapy. However, 
only 2 of  the subjects had done fetal haemoglobin assay. 
There is need for relevant authorities to make fetal hemo-
globin assay more accessible and affordable in order to 
facilitate monitoring therapeutic responses.
The recommended initial dose for initiation of  Hydroxy-
urea in SCD ranges about 10 – 20 mg/kg/day33,34. Dose 
escalation at 2.5 to 5 mg/kg is recommended every 4 
weeks to 6 months (average 8 weeks), till the maximum 
tolerable dose is achieved, while the patient is monitored 
for clinical and haematological responses. As a baseline 
and during drug titrations, evaluations for organ toxicities 
(renal and liver function tests) should be conducted every 
4 to 8 weeks. The ceiling dose for hydroxyurea in SCD is 
35 mg/kg33,34. The mean initial dose (at commencement 
of  therapy) of  hydroxyurea in the cohort was 10.61 mg/
kg/day although more of  the subjects started at a dose 
of  less than 10 mg/kg. Despite a median duration of  12 
months of  therapy, the current dose among the 20 sub-
jects on hydroxyurea was 13.49 mg/kg. This suggests that 
dose escalation or achievement of  maximum tolerable 
dose was not a major therapeutic target among prescrib-
ing physicians. This trend may be related to exercise of  
caution as regards marrow suppression and organ related 
toxicities, which could worsen patient morbidities. Possi-
bly, irregular use of  the drug, as well as the insignificant 
dose escalation may be related to low purchase power (in-
sufficient funds) among affected patients, who are major-
ly persons of  low or middle socio-economic class.
Three of  the subjects with history of  hydroxyurea use 
exercised fear regarding unknown adverse effects of  hy-
droxyurea such as its potential carcinogenic and terato-
genic effect, being a cytotoxic. However, 83.3% of  the 
subjects who used hydroxyurea reported good oral tol-
erance without toxicities. Others reported known side 
effects such as skin hyperpigmentation and rashes. One 
of  the subjects reported blurring of  vision and therapy 
had to be discontinued. Another patient reported dizzi-
ness but symptom resolved with dose reduction. Over 
the past two decades, studies have consistently shown a 
good safety profile with mild reversible short term toxici-
ties36,37. Though there is a theoretical risk, there is no sub-
stantial evidence that hydroxyurea increases the risk of  
blood cancers or solid tumors relative to the general pop-
ulation20,37. Prior to initiation of  therapy, treatment goals 
must be defined and detailed education on the drug must 
be provided to the patient. Patients should be reassured 
of  the safety profile of  hydroxyurea based on relevant 
data/existing literature. Patients should be counseled on 
regular follow-up to monitor for the expected clinical and 
haematological responses. Effectiveness of  treatment 
with hydroxyurea is related to compliance with daily use 
and patients should be counselled as such34. Absence of  
response after 12 months of  monitored therapy is an in-




Hydroxyurea shows significant prospects in ameliorating 
Nigerian SCD. However, there is still a relatively low level 
of  awareness, irregular use and absence of/poor compli-
ance with standard protocols in Nigeria. Large-scale lon-
gitudinal studies and clinical trials are needed to optimize 
the indications, dosing and safety profile of  hydroxyurea 
in the indigenous Nigerian population. Physicians and 
Nigerian SCD patients need to be educated continually 
on the clinical utility of  hydroxyurea. Barriers to its use 
should be elucidated through further research and proper 
interventions should be engaged. Governments, NGOs, 
Support agencies, pharmaceutical companies and other 
relevant stakeholders should engage in more active par-
ticipation regarding maximising hydroxyurea therapy in 
Nigerian SCD through advocacy, better funding, continu-
ous education/public enlightenments and other requisite 
strategies.
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